Cover Image

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England

Saved in:

Bibliographic Details
Main Authors:	Freja Cordelia Møller Kirsebom (Author), Nick Andrews (Author), Julia Stowe (Author), Natalie Groves (Author), Meera Chand (Author), Mary Ramsay (Author), Jamie Lopez Bernal (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
by: Catherine Quinot, et al.
Published: (2024)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
by: Urvashi B. Singh, et al.
Published: (2023)

Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2
by: Alwaleed Behzad, et al.
Published: (2024)

Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
by: Chengzhuo Tong, et al.
Published: (2022)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
by: Sivaprakasam T. Selvavinayagam, et al.
Published: (2022)

Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia
by: Abeer N. Alshukairi, et al.
Published: (2023)

Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
by: Kimiko Tomioka, et al.
Published: (2023)

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees
by: Francesca Dapporto, et al.
Published: (2022)

The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan
by: Jih-Jin Tsai, et al.
Published: (2024)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023)

Rapid investigation of BA.4/BA.5 cases in France
by: Alain-Claude Kouamen, et al.
Published: (2022)

Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2
by: Weijie Zhong, et al.
Published: (2023)

The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysis
by: Julia Stowe, et al.
Published: (2024)

Sub-registro de nascimento em Salvador, BA (Brasil) The under-registration of births in Salvador, BA (Brazil)
by: Maura Maria Guimarães de Almeida
Published: (1979)

Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland
by: Chris Robertson, et al.
Published: (2023)

Statement on healthcare system preparedness in response to COVID-19 Omicron subvariants BA.4 and BA.5 surge in Korea from the Korean Pediatric Society and Korean Society of Pediatric Infectious Diseases
by: Eun Young Cho, et al.
Published: (2022)

Case report: Severe acute hepatitis in a 22-month-old Chinese boy with Omicron sub-variant BA.2.38
by: Xinying Chen, et al.
Published: (2022)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024)

Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
by: Wenjing Ye, et al.
Published: (2023)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
by: Rahatul Islam, et al.
Published: (2023)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
by: Kana Fujimoto, et al.
Published: (2022)

Baboo Jabberjee, B.A.
by: Anstey, F., 1856-1934

Transmission characteristics of a COVID-19 outbreak caused by Omicron variant BA.5.2 in Yiwu city, China
by: Xiaoxiao WANG, et al.
Published: (2023)

Epidemiological characteristics of a local COVID-19 outbreak caused by Omicron (BA.2.2) variant in Henan province
by: Jing-jing PAN, et al.
Published: (2022)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022)

SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil.
by: Francisco P Freire-Neto, et al.
Published: (2022)

Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market
by: Mingyu Luo, et al.
Published: (2023)

Role of booster vaccines and hybrid immunity against severe COVID-19 outcomes during BA.5 omicron predominance in Thailand
by: Kannikar Intawong, et al.
Published: (2023)

Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
by: Shengnan Yin, et al.
Published: (2022)

Age-specific transmission dynamics under suppression control measures during SARS-CoV-2 Omicron BA.2 epidemic
by: Wenlong Zhu, et al.
Published: (2023)

Corrigendum: Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market
by: Mingyu Luo, et al.
Published: (2023)

As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
by: Ren Xu, et al.
Published: (2022)

Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection
by: Maja Sočan, et al.
Published: (2024)

DEVELOPMENT OF THE ECONOMY-MANAGEMENT COMPETENCIES BA IN ENGINEERING
by: Michail G. Minin, et al.
Published: (2016)

History of the Balkan Stomatological Society (BaSS)
by: Todorović Ljubomir
Published: (2014)

Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China
by: Wentao Zhu, et al.
Published: (2023)

Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
by: Baltazar Nunes, et al.
Published: (2024)

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection
by: Xiaosu Chen, et al.
Published: (2023)

Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
by: Nungruthai Suntronwong, et al.
Published: (2023)

Corrigendum: Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China
by: Wentao Zhu, et al.
Published: (2024)